Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

Title: Advancing Alzheimer’s Research: Cognition Therapeutics and ACTC’s Phase 2 START Study


Alzheimer’s disease is a devastating neurodegenerative disorder that affects millions of people worldwide. Finding effective treatments for Alzheimer’s has been a challenging task, but recent advancements in research offer new hope. Cognition Therapeutics and the Alzheimer’s Clinical Trials Consortium (ACTC) have received clearance from the US Food and Drug Administration (FDA) to begin the Phase 2 START study of oral CT1812 in early Alzheimer’s disease. In this blog post, we will delve into the key points behind this important study and its potential impact on Alzheimer’s treatment.

Key Points:

  1. Understanding Alzheimer’s Disease:

Alzheimer’s disease is a progressive brain disorder characterized by memory loss, cognitive decline, and behavioral changes. It is the most common form of dementia, affecting millions of individuals globally. Current treatments for Alzheimer’s only manage the symptoms temporarily, highlighting the urgency for new therapeutic options.

  1. CT1812: A Novel Approach to Alzheimer’s Treatment:

CT1812 is an investigational drug developed by Cognition Therapeutics. It is designed to target the toxic oligomers of amyloid-beta protein, which play a central role in the development and progression of Alzheimer’s disease. By blocking these toxic oligomers, CT1812 aims to preserve synaptic function and cognitive abilities in individuals with Alzheimer’s.

  1. Phase 2 START Study:

The Phase 2 START (Synaptic Targeting and Restore Trial) study, led by Cognition Therapeutics and the ACTC, will evaluate the safety, tolerability, and efficacy of oral CT1812 in people with early Alzheimer’s disease. The study will assess cognitive measures, biomarkers, and symptom progression over a treatment period of 26 weeks. This study represents a critical step in determining the potential of CT1812 as a disease-modifying therapy for Alzheimer’s.

  1. FDA Clearance:

The clearance from the FDA to initiate the Phase 2 START study is an essential milestone for Cognition Therapeutics and the entire Alzheimer’s research community. It validates the safety of CT1812 and the significance of its potential as a therapeutic intervention for Alzheimer’s disease. The partnership with the ACTC further strengthens the study’s credibility and paves the way for multi-centered clinical trials.

  1. Promising Preclinical Results:

Preclinical studies of CT1812 have shown encouraging results, demonstrating its ability to rescue synaptic connections, enhance cognition, and reduce amyloid-beta-induced toxicity. These findings provide a strong foundation for the Phase 2 study and support the hypothesis that targeting toxic oligomers could be a viable therapeutic strategy for Alzheimer’s disease.

  1. Potential Impact on Alzheimer’s Treatment:

If successful, CT1812 could represent a major breakthrough in the treatment of Alzheimer’s disease. By specifically targeting toxic oligomers, the drug has the potential to slow down or even halt the progression of the disease, preserving cognitive function and improving quality of life for individuals with Alzheimer’s. This would not only benefit patients but also their caregivers and families, who bear the emotional and financial burden of the disease.


The FDA clearance for the Phase 2 START study of oral CT1812 in early Alzheimer’s disease is a significant step forward in the search for effective treatments. Cognition Therapeutics and the ACTC’s collaborative effort offers new hope for individuals and families affected by Alzheimer’s. As we eagerly await the results of this study, it is a reminder that innovative research and clinical trials are crucial in the pursuit of transformative therapies that can combat the devastating impact of Alzheimer’s disease.